HIV treatment optimism should be balanced by need for "even more aggressive" therapies -- Harvard's Hammer.
HIV TREATMENT OPTIMISM MUST BE "TEMPERED" TO AVOID "COMPLACENCY" in the effort to develop AIDS treatments with long-term effectiveness, Harvard Medical School researcher Scott Hammer, MD, Harvard Medical School, cautioned in his keynote speech of the XI International Conference on AIDS in Vancouver. He suggested that the current level of excitement should serve as a catalyst to "spur even more intensive drug development efforts and the testing of even more aggressive therapeutic approaches."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth